

Reply to: “Neurodevelopmental Gene-Related Dystonia: A Pediatric Case with *NAA15* Variant”

We thank Yubero and colleagues for commenting on our recently published letter describing the manifestation of adult-onset dystonia-parkinsonism in association to a pathogenic *NAA15* *de-novo* nonsense variant.¹ Variants in *NAA15*, a gene involved in post-translational protein modifications via N-alpha-acetylation, have previously been shown to result in typical (neuro-)developmental disorder traits such as intellectual disability, behavioral disturbances, and craniofacial dysmorphisms (“Intellectual developmental disorder, autosomal dominant 50, with behavioral abnormalities”; MIM:617787).^{2,3} Yubero and colleagues have now identified an additional carrier of a (likely) pathogenic nonsense variant in *NAA15* who demonstrated dystonia as a leading clinical phenotype, thus confirming that abnormal (especially dystonic) movements can be part of the phenotypic spectrum of *NAA15*-related diseases. These aggregate findings, considered together with observations in large cohorts of individuals with *NAA15*-associated conditions,^{2,3} highlight that *NAA15* may be considered one of the many genes implicated in brain development whose mutational changes can give rise to (1) “classical” neurodevelopmental phenotypes without dystonia, (2) dystonia coexisting with neurodevelopmental features (ie, complex dystonia), or (3) seemingly isolated dystonia with no or only minor, difficult-to-recognize developmental comorbidity.⁴ Low rates of reported movement disorders in previous publications on *NAA15* disease subjects could be due to underdiagnosis. Therefore, we strongly agree with the proposition from Yubero and colleagues that patients presenting with intellectual disability and related traits, particularly if associated with rare neurodevelopmental gene variants, should be carefully screened for the expression of movement abnormalities, including dystonia. We note though that our recently published case with *NAA15* variant displayed movement-disorder characteristics markedly different from those reported in association to the *NAA15* alteration detected by Yubero and colleagues: their identified patient had limb dystonia with onset at the age of 3 years and no other movement disorders, whereas our individual manifested dystonia-parkinsonism in late adulthood.¹ Although Yubero and colleagues point out that many pediatric-onset neurodevelopmental movement disorders can worsen later in life, we really want to stress that our

case had no movement disorders before the age of 46 years. This raises important questions regarding variable expressivity and reduced penetrance of movement-disorder symptoms in the context of *NAA15* variants. Why do some individuals with *NAA15*-related disorders manifest late-onset combined movement disorders and some others childhood-onset dystonia, whereas the majority of cases do not seem to express abnormal movements at all (including the variant-positive mother of Yubero and colleagues’ patient)? Variant-specific effects, environmental influences, endogenous protective factors, multigenic inheritance, as-yet-undiscovered molecular determinants, or simply stochastic variations may play role.⁴ We hope that future multimodal research efforts will be able to clarify these mechanisms not only for *NAA15*-associated dystonia but also for other genetically determined movement disorders, which would have important implications for prognostication, treatment, and potentially preventive measures. ■

Acknowledgments: We thank the patients with *NAA15* variants for their generous participation.

Igor Straka, MD,¹ Jana Švantnerová, MD,¹ and
Michael Zech, MD^{2,3*} 

¹Second Department of Neurology, Faculty of Medicine, Comenius University, University Hospital Bratislava, Bratislava, Slovakia,

²Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany, and ³Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany

Data Availability Statement

Data available on request from the authors.

References

1. Straka I, Svantnerova J, Minar M, Stankova S, Zech M. Neurodevelopmental gene-related dystonia-parkinsonism with onset in adults: a case with *NAA15* variant. *Mov Disord* 2022;37(9):1955–1957.
2. Cheng H, Dharmadhikari AV, Varland S, et al. Truncating variants in *NAA15* are associated with variable levels of intellectual disability, autism spectrum disorder, and congenital anomalies. *Am J Hum Genet* 2018;102(5):985–994.
3. Cheng H, Gottlieb L, Marchi E, et al. Phenotypic and biochemical analysis of an international cohort of individuals with variants in *NAA10* and *NAA15*. *Hum Mol Genet* 2019;28(17):2900–2919.
4. Dzinovic I, Winkelmann J, Zech M. Genetic intersection between dystonia and neurodevelopmental disorders: insights from genomic sequencing. *Parkinsonism Relat Disord* 2022;102:131–140. doi:10.1016/j.parkreldis.2022.08.019.

© 2022 International Parkinson and Movement Disorder Society.

Key Words: dystonia; *NAA15*; neurodevelopmental disorder; variable expressivity

***Correspondence to:** Dr. Michael Zech, Institute of Neurogenomics, Helmholtz Zentrum München, Deutsches Forschungszentrum für

Gesundheit und Umwelt (GmbH), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany; E-mail: michael.zech@mri.tum.de

Received: 20 September 2022; **Accepted:** 21 September 2022

Published online in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.29242